Atossa Inks Deal for MASCT System; Buys Assets of Intraductal Dx, Therapy Firm | GenomeWeb

NEW YORK (GenomeWeb News) – Atossa Genetics disclosed in a regulatory filing that it has entered into a co-exclusive marketing deal for the MASCT System and acquired the assets of intraductal diagnostic and therapeutic firm Acueity Healthcare.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Cell this week: proteomic consequences of genomic changes in ovarian cancer, Human SRMAtlas, and more.

At Nature, John Wilbanks and Eric Topol call for openness in health data.

Law.com predicts that genomic and genetic testing will become common in toxic tort cases.

A Pew Research Center report finds that most Americans are wary of using technologies like gene editing to enhance human abilities.